<?xml version="1.0" encoding="UTF-8"?>
<p id="p0085">
 <xref rid="bib16" ref-type="bibr">Gastaminza et al., (2010)</xref> suggested that chlorpromazine inhibits clathrin-dependent endocytosis of the HCV, which is also enveloped, positive-stranded RNA virus as coronaviruses (
 <xref rid="bib16" ref-type="bibr">Gastaminza et al., 2010</xref>). Chlorpromazine as a cationic amphiphilic drug inhibits HCV infection during virus-host cell fusion (intercalate into the cholesterol-rich domains of the host cell membrane and increases membrane fluidity) (
 <xref rid="bib12" ref-type="bibr">Dyall et al., 2017</xref>). The anti-HCV activity of chlorpromazine was also analyzed by 
 <xref rid="bib6" ref-type="bibr">Chamoun-Emanuelli et al. (2013)</xref>. The obtained IC
 <sub>50</sub> value was 1.47 ± 0.32 μM and a therapeutic index (CC
 <sub>50</sub>/IC
 <sub>50</sub>) was 6 (
 <xref rid="bib6" ref-type="bibr">Chamoun-Emanuelli et al., 2013</xref>). Moreover, the drug is capable to inhibit the replication hepatitis C virus (
 <xref rid="bib12" ref-type="bibr">Dyall et al., 2017</xref>; 
 <xref rid="bib45" ref-type="bibr">Pillaiyar et al., 2015</xref>) and mouse hepatitis virus-2 (MHV-2) (
 <xref rid="bib45" ref-type="bibr">Pillaiyar et al., 2015</xref>).
</p>
